Verified Clinical Trials, the global leader in clinical trial subject registry solutions, has entered a new partnership with WindRose Health Investors to begin an exciting new chapter of growth.
VCT’s industry-recognised subject registry platform is designed to support patient safety, compliance and data integrity from enrolment through study completion. VCT detects and helps prevent duplicate enrolment and other important protocol violations at the time of screening – issues that compromise research subject safety, affect data quality, create operational and regulatory challenges and increase the risk of study failure.
The investment from WindRose reflects VCT’s immense value to sponsors, CROs, research sites, and ultimately research subjects by strengthening the integrity of clinical research data, reducing preventable risk and improving safety.
VCT will maintain its name, brand, and commitments to safety, data quality, and strong client partnerships, but will have additional capital to support investment in infrastructure and expansion of services and geographic reach.
To accelerate the next phase of growth, Howard Miller will join VCT as the next Chief Executive Officer. He brings more than 30 years of experience leading healthcare and life sciences companies, including serving as CEO of Envision Pharma Group, COO and then CEO at Two Labs, and in sales and marketing leadership roles at Abbott, Cardinal Health and Novavax.
Co-founders Mitchell Efros MD, and Kerri Weingard ANP, will remain fully engaged in the business and their roles will evolve to focus on long-term strategy and how VCT can deepen its impact across the clinical trials industry. Mitchell will serve as President and Co-Founder, focusing on client relationships and enhancement of the company’s value proposition. Kerri will serve as Chief of Strategic Operations, focusing on how VCT drives continuous improvement at scale.
